Biolase Stock Analysis

BIOL -  USA Stock  

USD 0.34  0.02  5.56%

The big decline in price over the last few months for Biolase could raise concerns from stakeholders as the firm it trading at a share price of 0.34 on 2,682,955 in volume. The company executives failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Biolase or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.24. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Biolase partners.
Continue to Trending Equities.

Biolase Stock Analysis 

 
Refresh
The Biolase stock analysis report makes it easy to digest most publicly released information about Biolase and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Biolase Stock analysis module also helps to analyze the Biolase price relationship with some important fundamental indicators such as market cap and management efficiency.

Biolase Stock Analysis Notes

About 19.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.91. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biolase recorded a loss per share of 0.13. The entity next dividend is scheduled to be issued on the 24th of June 2005. The firm had 201:200 split on the 11th of May 2018. BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California. Biolase operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 135 people. For more info on Biolase please contact Harold Flynn at 949 361-1200 or go to www.biolase.com.

Biolase Quarterly Cost of Revenue

4.69 MillionShare

Biolase Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Biolase's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Biolase or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Biolase generated a negative expected return over the last 90 days
Biolase has some characteristics of a very speculative penny stock
Biolase has high historical volatility and very poor performance
Biolase has a very high chance of going through financial distress in the upcoming years
Biolase was previously known as Biolase and was traded on NASDAQ Exchange under the symbol BLTI.
The company reported the previous year's revenue of 35.3 M. Net Loss for the year was (17.57 M) with profit before overhead, payroll, taxes, and interest of 6.17 M.
Biolase currently holds about 33.38 M in cash with (14.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22.
Biolase has a frail financial position based on the latest SEC disclosures
Latest headline from www.marketbeat.com: BIOLASE, Inc. Expected to Post FY2021 Earnings of Per Share - MarketBeat

Biolase Upcoming and Recent Events

Earnings reports are used by Biolase to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biolase previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of March 2022
Next Earnings Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Biolase Largest EPS Surprises

Earnings surprises can significantly impact Biolase's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-11-10
2021-09-30-0.025-0.02070.004317 
2014-11-04
2014-09-30-0.09-0.080.0111 
2021-08-12
2021-06-30-0.035-0.02160.013438 
View All Earnings Estimates

Biolase SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Biolase prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Biolase investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Biolase specific information freely available to individual and institutional investors to make a timely investment decision.
10th of January 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
8th of December 2021
Other Events
View
23rd of November 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Entry into a Material Definitive Agreement
View
18th of November 2021
Other Events
View
17th of November 2021
Financial Statements and Exhibits. Other Events
View
10th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
12th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
2nd of July 2021
Unclassified Corporate Event
View

Biolase Thematic Classifications

In addition to having Biolase stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Medical Equipment IdeaMedical Equipment
USA Equities from Medical Equipment industry as classified by Fama & French

Biolase Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Biolase is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biolase backward and forwards among themselves. Biolase's institutional investor refers to the entity that pools money to purchase Biolase's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Tarbox Family Office IncCommon Shares7.8 KK
Ifp Advisors IncCommon Shares2.1 KK
Koshinski Asset Management IncCommon SharesK1.2 K
Huntington National BankCommon Shares1.00.0
Parallel Advisors LlcCommon Shares100.00.0
Vanguard Group IncCommon SharesM4.5 M
Perkins Capital Management IncCommon Shares3.1 MM
Note, although Biolase's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Biolase Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 57.88 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biolase's market, we take the total number of its shares issued and multiply it by Biolase's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Biolase Profitablity

Biolase's profitability indicators refer to fundamental financial ratios that showcase Biolase's ability to generate income relative to its revenue or operating costs. If, let's say, Biolase is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Biolase's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Biolase's profitability requires more research than a typical breakdown of Biolase's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (48.22) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (51.83) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.52.
Last ReportedProjected for 2022
Return on Investment(56.73) (61.21) 
Return on Average Assets(0.45) (0.48) 
Return on Average Equity(2.98) (3.06) 
Return on Invested Capital(0.97) (1.05) 
Return on Sales(0.57) (0.58) 

Management Efficiency

The entity has return on total asset (ROA) of (23.07) % which means that it has lost $23.07 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (77.07) %, meaning that it created substantial loss on money invested by shareholders. Biolase management efficiency ratios could be used to measure how well biolase manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Investment is estimated to pull down to -61.21. The value of Return on Average Assets is estimated to pull down to -0.48. Biolase Revenue to Assets are relatively stable at the moment as compared to the past year. The company's current value of Revenue to Assets is estimated at 1.56. Total Assets Per Share is expected to hike to 0.86 this year, although the value of Net Current Assets as percentage of Total Assets will most likely fall to 29.16.
Last ReportedProjected for 2022
Book Value per Share 0.15  0.15 
Enterprise Value over EBIT(3.45) (3.72) 
Enterprise Value over EBITDA(3.12) (3.36) 
Price to Book Value 4.44  4.56 
Tangible Assets Book Value per Share 0.56  0.57 
Enterprise Value33.8 M41.9 M
Tangible Asset Value43.8 M43.9 M

Technical Drivers

As of the 24th of January, Biolase shows the risk adjusted performance of (0.14), and Mean Deviation of 3.27. Biolase technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for Biolase, which can be compared to its rivals. Please confirm Biolase coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Biolase is priced correctly, providing market reflects its regular price of 0.34 per share. As Biolase appears to be a penny stock we also recommend to validate its total risk alpha numbers.

Biolase Price Movement Analysis

The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The MESA Adaptive Moving Average indicator adapts to Biolase price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator. View also all equity analysis or get more info about mesa adaptive moving average overlap studies indicator.

Biolase Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biolase insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biolase's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biolase insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Biolase Predictive Daily Indicators

Biolase intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biolase stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Biolase Forecast Models

Biolase time-series forecasting models is one of many Biolase's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biolase's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Biolase Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Biolase stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biolase shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Biolase. By using and applying Biolase Stock analysis, traders can create a robust methodology for identifying Biolase entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(33.21) (35.83) 
EBITDA Margin(0.55) (0.56) 
Gross Margin 0.24  0.28 
Profit Margin(0.67) (0.68) 
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California. Biolase operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 135 people.

Current Biolase Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Biolase analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Biolase analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
2.0Buy3Odds
Biolase current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Biolase analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Biolase stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Biolase, talking to its executives and customers, or listening to Biolase conference calls.
Biolase Analyst Advice Details

Biolase Stock Analysis Indicators

Biolase stock analysis indicators help investors evaluate how Biolase stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Biolase shares will generate the highest return on investment. By understating and applying Biolase stock analysis, traders can identify Biolase position entry and exit signals to maximize returns.
Quick Ratio2.75
Fifty Two Week Low0.3700
Revenue Growth45.80%
Average Daily Volume Last 10 Day2.15M
Shares Short Prior Month6.82M
Average Daily Volume In Three Month3.44M
Shares Percent Shares Out4.34%
Gross Margins35.49%
Forward Price Earnings-4.20
Short Percent Of Float4.43%
Float Shares149.67M
Fifty Two Week High1.5100
Fifty Day Average0.4380
Enterprise Value To Ebitda-2.40
Two Hundred Day Average0.6189
Enterprise Value To Revenue1.24
Continue to Trending Equities. Note that the Biolase information on this page should be used as a complementary analysis to other Biolase's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Biolase Stock analysis

When running Biolase price analysis, check to measure Biolase's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biolase is operating at the current time. Most of Biolase's value examination focuses on studying past and present price action to predict the probability of Biolase's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biolase's price. Additionally, you may evaluate how the addition of Biolase to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Is Biolase's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biolase. If investors know Biolase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biolase listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biolase is measured differently than its book value, which is the value of Biolase that is recorded on the company's balance sheet. Investors also form their own opinion of Biolase's value that differs from its market value or its book value, called intrinsic value, which is Biolase's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biolase's market value can be influenced by many factors that don't directly affect Biolase's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biolase's value and its price as these two are different measures arrived at by different means. Investors typically determine Biolase value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biolase's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.